The Role of Biologic Therapy for Psoriasis in Cardiovascular Risk Reduction

Mr. No is from the School of Medicine, Loma Linda University, California. Ms. Amin is from the School of Medicine, University of California, Riverside. Dr. Egeberg is from the Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Denmark. Dr. Wu is from the Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, California.

Mr. No and Ms. Amin report no conflict of interest. Dr. Egeberg has received research funding from Eli Lilly and Company and Pfizer Inc and honoraria as consultant and/or speaker from Eli Lilly and Company; Galderma Laboratories, LP; Janssen; Novartis; and Pfizer Inc. Dr. Wu has received research funding from AbbVie Inc; Amgen Inc; AstraZeneca; Boehringer Ingelheim; Coherus BioSciences Inc; Dermira Inc; Eli Lilly and Company; Janssen; Merck & Co, Inc; Novartis; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sandoz, A Novartis Division; and Sun Pharmaceutical Industries Ltd. He also is a consultant for AbbVie Inc; Amgen Inc; AstraZeneca; Celgene Corporation; Dermira Inc; Eli Lilly and Company; LEO Pharma; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sun Pharmaceutical Industries Ltd; and Valeant Pharmaceuticals International, Inc. All funds go to his employer.

Correspondence: Jashin J. Wu, MD, Kaiser Permanente Los Angeles Medical Center, Department of Dermatology, 1515 N Vermont Ave, 5th Floor, Los Angeles, CA 90027 (jashinwu@gmail.com).